Trial Profile
Third phase II/III study of REM-001 for the treatment of cutaneous (skin surface) metastatic breast cancer (CMBC)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Rostaporfin (Primary)
- Indications Advanced breast cancer; Skin cancer
- Focus Therapeutic Use
- 14 Feb 2023 According to a Kintara Therapeutics media release, FDA has granted Fast Track Designation for Kintara's REM-001 therapy for the treatment of patients with cutaneous metastatic breast cancer (mBC).
- 21 Jan 2016 New trial record